Endocrinology: Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer

January 2, 2020

Sulgi Park, Chung-Seog Song, Chun-Lin Lin, Shoulei Jiang, Pawel A Osmulski, Chiou-Miin Wang, Brett T Marck, Alvin M Matsumoto, Colm Morrissey, Maria E Gaczynska, Yidong Chen, Elahe A Mostaghel, Bandana Chatterjee Abstract SULT2B1b (SULT2B) is a prostate-expressed hydroxysteroid sulfotransferase, which may regulate intracrine androgen homeostasis by mediating 3β-sulfation of dehydroepiandrosterone (DHEA), the precursor for 5α-dihydrotestosterone (DHT) biosynthesis. The aldo-keto reductase (AKR)1C3 regulates androgen receptor (AR) activity in […]

Frontiers in Biosciences (Elite Ed) Cytogenetics of hepatoblastoma

January 2, 2020

Gail E Tomlinson 1 Abstract The cytogenetics of hepatoblastoma demonstrate recurring events which include whole chromosome trisomies, most commonly trisomy of chromosome 2, 8, or 10. In addition, unbalanced translocations involving a breakpoint on the proximal short arm of chromosome 1 are observed which results in a duplication of the long arm of chromosome 1q. The […]

Molecular Cancer Research: ELF4 is a target of miR-124 and promotes neuroblastoma proliferation and undifferentiated state

January 1, 2020

Adam Kosti, Liqin Du, Haridha Shivram, Mei Qiao, Suzanne Burns, Juan Gabriel Garcia, Alexander Pertsemlidis, Vishwanath R Iyer, Erzsebet Kokovay, Luiz OF Penalva 13-Cis-retinoic acid (RA) is typically used in postremission maintenance therapy in patients with neuroblastoma. However, side effects and recurrence are often observed. We investigated the use of miRNAs as a strategy to […]

Scientific Reports: Genomic analyses of early responses to radiation in glioblastoma reveal new alterations at transcription, splicing, and translation levels

January 1, 2020

Choudhary Saket, Suzanne C Burns, Mirsafian Hoda, Wenzheng Li, Dat T Vo, Qiao Mei, Lei Xiufen, Andrew D Smith, Luiz O Penalva High-dose radiation is the main component of glioblastoma therapy. Unfortunately, radio-resistance is a common problem and a major contributor to tumor relapse. Understanding the molecular mechanisms driving response to radiation is critical for […]

bioRxiv: Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches

January 1, 2020

Sajina Shakya, Anthony D Gromovsky, James S Hale, Arnon M Knudsen, Briana Prager, Lisa C Wallace, Luiz OF Penalva, Pavlina Ivanova, H Alex Brown, Bjarne W Kristensen, Jeremy N Rich, Justin D Lathia, J Mark Brown, Christopher G Hubert Background: Glioblastoma (GBM) is marked by cellular heterogeneity, including metabolic heterogeneity, that varies among cellular microenvironments […]

BMG Genomics: An ancestry informative marker panel design for individual ancestry estimation of Hispanic population using whole exome sequencing data

December 30, 2019

Li-Ju Wang, Catherine W. Zhang, Sophia C. Su, Hung-I H. Chen, Yu-Chiao Chiu, Zhao Lai, Hakim Bouamar, Amelie G. Ramirez, Francisco G. Cigarroa, Lu-Zhe Sun & Yidong Chen Abstract Background Europeans and American Indians were the major genetic ancestry of Hispanics in the U.S. These ancestral groups have markedly different incidence rates and outcomes in many types of cancers. Therefore, the genetic admixture may cause a […]

Molecular Carcinogenesis: PELP1 signaling contributes to medulloblastoma progression by regulating the NF‐κB pathway

December 24, 2019

Yiliao Luo Mengxing Li Uday P. Pratap Suryavathi Viswanadhapalli Junhao Liu Prabhakar P. Venkata Kristin A. Altwegg Bridgitte E. Palacios Xiaonan Li Yihong Chen Manjeet K. Rao Andrew J. Brenner Gangadhara R. Sareddy Ratna K. Vadlamud Abstract Medulloblastoma (MB) is the most common and deadliest brain tumor in children. Proline‐, glutamic acid‐, and leucine‐rich protein […]

Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

December 17, 2019

The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both preclinical and clinical testing, necessitating TMZ dose reduction to ~15% of the single-agent maximum tolerated dose. We […]

Technology News Network: Team Develop Drugs To Fight Leukemia and Lymphoma

December 9, 2019

UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2. “This is a new class of drugs called PROTACs that target […]